We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 304.00 | 304.00 | 306.00 | 312.00 | 304.00 | 312.00 | 19,411 | 12:33:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
TIDMHCM
RNS Number : 7461E
Hutchison China Meditech Limited
22 October 2018
Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").
Chi-Med granted 43,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:
Date of grant : October 19, 2018 Exercise price of share options : GBP46.10 per Ordinary Share granted Number of share options granted : 43,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share) Closing market price of Ordinary : GBP46.10 per Ordinary Share Shares on the date of grant Validity period of the share : From October 19, 2018 to October options 18, 2028
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile) xyang@troutgroup.com Media Enquiries UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile) jlo@brunswickgroup.com Mainland China - Sam Shen, Edelman +86 1367 179 1029 (Mobile) sam.shen@edelman.com Nominated Advisor Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
POSPGGUUUUPRUBP
(END) Dow Jones Newswires
October 22, 2018 05:05 ET (09:05 GMT)
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions